An Open-Label, 2-Period Sequential Drug Interaction Study to Evaluate the Effect of a 100 Mg Dose of Desvenlafaxine SR on the Pharmacokinetics of Aripiprazole When Coadministered in Healthy Subjects.

Trial Profile

An Open-Label, 2-Period Sequential Drug Interaction Study to Evaluate the Effect of a 100 Mg Dose of Desvenlafaxine SR on the Pharmacokinetics of Aripiprazole When Coadministered in Healthy Subjects.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Sep 2011

At a glance

  • Drugs Aripiprazole; Desvenlafaxine
  • Indications Attention-deficit hyperactivity disorder; Behavioural disorders; Bipolar disorders; Depressive disorders; Gilles de la Tourette's syndrome; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Nov 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 23 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top